| 1 |
31183223 | Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature. | 2019 |
2 |
| 2 |
31818296 | Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up. | 2019 Dec 9 |
2 |
| 3 |
28458907 | Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy. | 2017 |
1 |
| 4 |
29263719 | The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome. | 2017 May-Aug |
1 |
| 5 |
24443791 | Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. | 2014 Jun |
2 |
| 6 |
22970022 | Expression and subcellular localization of menin in human cancer cells. | 2012 Jun |
1 |
| 7 |
18485119 | Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. | 2008 Nov |
3 |
| 8 |
10570446 | Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis. | 1999 Nov 15 |
3 |